- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Freedland on Treating Early-Stage Prostate Cancer
October 31st 2012, 2:38pm
Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.
Tracking the Oncology Pipeline: Developments From ESMO
October 25th 2012, 7:27am
The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.
Photos From the 2012 NCONN Conference
October 8th 2012, 1:04pm
Photos from the 2012 National Coalition of Oncology Nurse Navigators' (NCONN) annual conference that was held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, Tennessee.
New Metastatic Melanoma Therapies Create Hope for Patients, Key Role for Oncology Nurses
October 8th 2012, 12:55pm
The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.
Opportunity Knocks: New ACoS Standard Requires Navigation Process in Place by 2015
October 8th 2012, 10:35am
Facilities seeking Commission on Cancer accreditation now need to have a patient navigation process in place by 2015.
Beth DuPree, MD, Updates Navigators on Breast Cancer Treatments
October 8th 2012, 6:49am
Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.
Cristi Radford on the Nurse Navigator's Role in Genetic Counseling
October 5th 2012, 8:39am
Cristi Radford, a Certified Genetic Counselor, explains the multifaceted role that oncology nurse navigators play in the genetic counseling process.
Dr. Cohen on the Cabozantinib Dosage and Tolerability
October 4th 2012, 7:25am
Ezra Cohen, MD, from the University of Chicago Medical Center, discusses the impact of cabozantinib's dose size on tolerability.
Photos From the European Society for Medical Oncology Congress
October 3rd 2012, 1:18pm
Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.
In Refractory GIST, Regorafenib Delays Disease Progression Across All Subgroups
October 3rd 2012, 10:14am
Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.
Long-Term Data Show Significant Improvement in Survival With Ipilimumab in Melanoma
October 3rd 2012, 8:50am
Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.
One Year of Adjuvant Trastuzumab Remains Standard of Care
October 3rd 2012, 6:33am
Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.
Bevacizumab Plus Chemotherapy Improves Response Rates and PFS in Platinum-Resistant Ovarian Cancer
October 2nd 2012, 11:48am
An exploratory analysis of the phase III AURELIA trial affirms the benefit of adding bevacizumab to chemotherapy for patients with platinum-resistant recurrent ovarian cancer.
No Survival Advantage for Ifosfamide Added to Doxorubicin in Advanced Soft Tissue Sarcoma
October 2nd 2012, 9:53am
The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.
Pazopanib Another Front-Line Therapy Option for Metastatic Renal Cell Carcinoma
October 2nd 2012, 9:10am
Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.
Updated Data Show T-DM1 Improves Overall Survival in HER2-Positive Breast Cancer
October 1st 2012, 11:35am
An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.
Positive Results in ALK-Positive NSCLC With First ALK Inhibitor
October 1st 2012, 8:38am
Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.
Updated Regorafenib Survival Results Confirm Effectiveness
October 1st 2012, 7:48am
Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.
Dr. Ezra Cohen on the Pharmacokinetics of Cabozantinib
September 30th 2012, 1:55pm
Ezra E.W. Cohen, MD, from the University of Chicago Medical Center, on the pharmacokinetics and efficacy of cabozantinib for medullary thyroid cancer.
Does Docetaxel Add Benefit to the Oral Fluoropyrimidine S-1 in Gastric Cancer?
September 30th 2012, 5:10am
Two analyses, two different conclusions in Asian START trial when docetaxel was added to S-1 for patients with previously untreated advanced or recurrent gastric cancer.